Last reviewed · How we verify
Iodixanol 320-Arm 1
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.
Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures. Used for Coronary angiography and percutaneous coronary intervention, Peripheral vascular angiography, Renal artery imaging.
At a glance
| Generic name | Iodixanol 320-Arm 1 |
|---|---|
| Also known as | Visipaque |
| Sponsor | GE Healthcare |
| Drug class | Iso-osmolar contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging / Radiology |
| Phase | FDA-approved |
Mechanism of action
Iodixanol contains iodine atoms that absorb X-rays, creating contrast between different tissue densities on radiographic images. As an iso-osmolar contrast medium (osmolality ~290 mOsm/kg, matching blood), it is designed to minimize osmotic stress on cells and reduce nephrotoxicity compared to hyperosmolar contrast agents. It is used intravenously during angiography, coronary interventions, and other vascular imaging procedures.
Approved indications
- Coronary angiography and percutaneous coronary intervention
- Peripheral vascular angiography
- Renal artery imaging
- General vascular and cardiac imaging procedures
Common side effects
- Contrast-induced nephropathy (acute kidney injury)
- Allergic reactions (mild to severe)
- Nausea and vomiting
- Hypersensitivity reactions
- Thrombosis
Key clinical trials
- Intra-discal Steroid Injection for MODIC I Discopathy (PHASE4)
- Comparison of Contrast Agents During CT Angiography (NA)
- Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease (PHASE4)
- Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography (PHASE4)
- Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodixanol 320-Arm 1 CI brief — competitive landscape report
- Iodixanol 320-Arm 1 updates RSS · CI watch RSS
- GE Healthcare portfolio CI